Paris, France

Pierrick Rival

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Sanofi. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Pierrick Rival

Introduction

Pierrick Rival is a notable inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the area of RNA compositions. His work focuses on innovative methods for inhibiting gene expression, which has important implications for medical treatments.

Latest Patents

Pierrick Rival holds a patent for "RNA compositions and methods for inhibiting ANGPTL8." This patent relates to double-stranded RNAs (dsRNAs) that target ANGPTL8, methods for inhibiting ANGPTL8 gene expression, and approaches for treating conditions associated with ANGPTL8 gene expression. His innovative work in this area demonstrates the potential for RNA-based therapies in addressing various health issues.

Career Highlights

Rival is currently employed at Sanofi, a leading global healthcare company. His role at Sanofi allows him to collaborate with other experts in the field and contribute to groundbreaking research and development in biotechnology. His career reflects a commitment to advancing medical science through innovative solutions.

Collaborations

Pierrick Rival has worked alongside esteemed colleagues such as Bodo Brunner and Armin Hofmeister. These collaborations enhance the research environment and foster the exchange of ideas, leading to more effective solutions in the field of biotechnology.

Conclusion

In summary, Pierrick Rival is a distinguished inventor whose work in RNA compositions and gene expression inhibition is paving the way for new medical treatments. His contributions at Sanofi and collaborations with other experts highlight his dedication to innovation in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…